Harry Resin - Pharmadrug Pres Smart
| LMLLF Stock | USD 0.01 0.0005 4.63% |
Insider
Harry Resin is Pres Smart of Pharmadrug
| Phone | 647 202 1824 |
| Web | https://www.pharmadrug.ca |
Pharmadrug Management Efficiency
The company has return on total asset (ROA) of (0.1883) % which means that it has lost $0.1883 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5928) %, meaning that it generated substantial loss on money invested by shareholders. Pharmadrug's management efficiency ratios could be used to measure how well Pharmadrug manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | INSIDER Age | ||
| Brian Sherman | Cannara Biotech | N/A | |
| Zohar Krivorot | Cannara Biotech | 46 | |
| Feng Zhou | China SXT Pharmaceuticals | 32 | |
| France Landry | Cannara Biotech | N/A | |
| Anthony Manouk | Cannara Biotech | N/A | |
| David Abitbol | Cannara Biotech | N/A | |
| Julia Bouvet | Cannara Biotech | N/A | |
| Etienne Ledoux | Cannara Biotech | N/A | |
| Avi Krivorot | Cannara Biotech | N/A | |
| Xiaodong Pan | China SXT Pharmaceuticals | 46 | |
| Alexander Wolfe | Cannara Biotech | N/A | |
Management Performance
| Return On Equity | -0.59 | |||
| Return On Asset | -0.19 |
Pharmadrug Leadership Team
Elected by the shareholders, the Pharmadrug's board of directors comprises two types of representatives: Pharmadrug inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharmadrug. The board's role is to monitor Pharmadrug's management team and ensure that shareholders' interests are well served. Pharmadrug's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharmadrug's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Harry Resin, Pres Smart | ||
| Paul Slyke, Chief Officer | ||
| Daniel Cohen, Chairman CEO | ||
| Keith CPA, Chief Officer |
Pharmadrug Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Pharmadrug a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.59 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (10.08) % | |||
| Current Valuation | 4.43 M | |||
| Shares Outstanding | 355.63 M | |||
| Shares Owned By Insiders | 1.88 % | |||
| Price To Book | 0.55 X | |||
| Price To Sales | 7.86 X | |||
| Revenue | 494.99 K | |||
| Gross Profit | 182.04 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Pharmadrug Pink Sheet
Pharmadrug financial ratios help investors to determine whether Pharmadrug Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmadrug with respect to the benefits of owning Pharmadrug security.